The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I)； or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.本発明は，式（Ｉ）の化合物から選ばれるＣＤＫ阻害剤又は薬剤学的に許容し得るその塩とソラフェニブ，ラパチニブ，エルロチニブ，シスプラチン，５－フルオロウラシル，ドセタキセル又はセツキシマブ又は薬剤学的に許容し得るそれらの塩を含む，扁平上皮癌の治療において用いる薬剤組合せに関する。当該薬物組合せは頭頸部扁平上皮癌（SCCHN）の治療に用いられたとき相乗作用を示す。本発明は，当該組合せを含む薬剤組成物に，また，当該組合せの治療上有効量を用いて頭頸部扁平上皮癌（SCCHN）を治療するための方法にも関する。
